This study is designed to determine if systemic concentrations of the bone active cytokine IL-6 and its soluble receptor are increased in patients with certain diseases (primary and secondary hyperparathyroidism, humoral hypercalcemia of malignancy, multiple myeloma and thyrotoxicosis).
Showing the most recent 10 out of 600 publications